Jump to content

Antisoma announces positive ASA404 presentations at ASCO


RandyW

Recommended Posts

LONDON -- 05/30/08 -- Antisoma (LSE: ASM; USOTC:ATSMY) announces today details of two presentations on ASA404 that will be made at the upcoming 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO):

Abstract no. 8072 (poster) Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404); M. J. McKeage, M. B. Jameson, AS1404-201 Study Group Investigators; on Sunday 1 June, 2-6pm - Board 45c, in S Hall A1.

Abstract no. 5007 (oral presentation) Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study; R. Pili, M. Rosenthal, AS1404-203 study group investigators; on Monday 2 June, 11.30-11.45am in Clinical Science Symposium on 'Novel antiangiogenic mechanisms' in Room W375a.

Enquiries:

Glyn Edwards, CEO

Daniel Elger, Director of Communications +44 (0)7909 915 068

Antisoma plc

Mark Court/Lisa Baderoon/Rebecca Skye +44 (0)20 7466 5000

Dietrich

Buchanan Communications

Brian Korb +1 646 378 2923

The Trout Group

Link to comment
Share on other sites

Randy:

Re your above-noted Abstract 8072, the following is the abstract as published by ASCO:

http://www.asco.org/ASCO/Abstracts+%26+ ... ctID=31916

Abstracts > 2008 ASCO Annual Meeting

Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404).

Sub-category: Metastatic Lung Cancer

Category: Lung Cancer--Metastatic Lung Cancer

Meeting: 2008 ASCO Annual Meeting

Abstract No: 8072

Citation: J Clin Oncol 26: 2008 (May 20 suppl; abstr 8072)

Author(s): M. J. McKeage, M. B. Jameson, AS1404-201 Study Group Investigators

Abstract:

Background: DMXAA (ASA404) is a tumor vascular disrupting agent recently evaluated in phase II trials in NSCLC. A randomized trial compared DMXAA 1,200 mg/m2 plus carboplatin and paclitaxel (CP) with CP alone (median survival 14.0 vs 8.8 months). A single-arm study evaluated DMXAA 1,800 mg/m2 plus CP (median survival 14.9 months). Both trials included squamous and non-squamous patients. We examined whether the safety or efficacy of DMXAA varied with histology.

Methods: Patients had chemotherapy-naïve stage IIIb/IV NSCLC. Phase II data were pooled by histology and treatment, with aggregation of the two DMXAA doses. We compared efficacy and safety between squamous and non-squamous patients receiving the same treatment. Then for each histology we compared patients receiving and not receiving DMXAA.

Results: Numbers of patients evaluable for safety (efficacy) were: in the CP arm of the randomized study, 11 (11) squamous and 25 (25) non-squamous; in the CP + DMXAA 1,200 mg/m2 arm of the randomized study, 11 (11) squamous and 26 (23) non-squamous; and in the CP + DMXAA 1,800mg/m2 single arm study, 11 (10) squamous and 20 (20) non-squamous. Pooling data from the two DMXAA dose groups should not introduce bias because they contain similar proportions of squamous patients.

Conclusions: Addition of DMXAA to CP was generally well tolerated in both squamous and non- squamous patients. There was no evidence that DMXAA induced hemoptysis in either group. In both squamous and non-squamous patients, efficacy findings including survival were consistently better with DMXAA plus CP than with CP alone. The forthcoming phase III trial will therefore include both squamous and non-squamous patients. Safety and Efficacy

Squamous Non-squamous All histologies

CP CP + DMXAA CP CP + DMXAA CP CP + DMXAA

% patients with >1 adverse event NCI-CTC grade >3/severe 72.7% (n=11) 68.2% (n=22) 64.0% (n=25) 60.9% (n=46) 66.7% (n=36) 63.2% (n=68)

Response rate* 14.3% (n=7) 40.0% (n=20) 25.0% (n=20) 31.7% (n=41) 22.2% (n=27) 34.4% (n=61)

Median time to tumor progression (months) 1.6 (n=11) 5.6 (n=21) 4.8 (n=25) 5.5 (n=43) 4.4 (n=36) 5.5 (n=64)

Median survival (months) 5.5 (n=11) 10.2 (n=21) 11.0 (n=25) 14.9 (n=43) 8.8 (n=36) 14.5 (n=64)

*12 patients evaluable for other efficacy parameters were not evaluable for response.

Associated Presentation(s):

1. Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404).

No presentation available, please check back

Meeting: 2008 ASCO Annual Meeting

Presenter: Mark J McKeage

Session: Lung Cancer — Metastatic (General Poster Session)

© 2005-2008 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.

----------

Thanks for bringing this to my attention, Randy!

Carole

Life is a Terminal Condition

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...